IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
IO Biotech has an experienced management team within the immune-oncology field and a world-class advisory board.
Company Details
- Employees
- 94
- Founded
- -
- Address
- Ole Maaloesvej 3, Copenhagen,denmark 2200,denmark
- Phone
- (452)194-7856
- mz****@****ech.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- iobiotech.com
- Keywords
- Cancer Vaccines and Immuno-oncology.
- HQ
- Copenhagen, Denmark
Io Biotech Questions
Io Biotech's helpline number is (452)194-7856
Io Biotech's website is iobiotech.com
Io Biotech's LinkedIn profile is https://dk.linkedin.com/company/io-biotech
Io Biotech has
94 employees.
View email and phone details for 94
employees at Io Biotech.
Io Biotech's industry is
Biotechnology Research
Io Biotech's top competitors are
Minervax Aps,
Zealand Pharma,
Evaxion A/s,
Immudex,
Acesion Pharma,
Hemab Therapeutics,
Adcendo,
Hoba Therapeutics,
Genmab,
Nordic Bioscience.
Io Biotech's support email address is mz@iobiotech.com
Io Biotech's categories are Biotechnology Research
Io Biotech's founding year is 2015
